Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Fudan University

Status and phase

Enrolling

Phase 2

Conditions

Triple-negative Breast Cancer

Treatments

Drug: Dasatinib

Drug: Quercetin

Drug: Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum

Study type

Interventional

Funder types

Other

Identifiers

NCT06355037

B2024.1.30

Details and patient eligibility

About

Full description

This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of dasatinib, quercetin with chemotherapy in mTNBC (triple negative breast cancer) patients who progressed during previous chemotherapy. Chemotherapy is the backbone drug for TNBC. How to reverse chemotherapy resistance or how to increase the sensitivity of chemotherapy efficacy, has become an urgent clinical problem to be solved. Our preclinical studies have demonstrated that the combination of dasatinib and quercetin with chemotherapy can effectively eliminate chemotherapy-induced senescent fibroblasts, decrease the proliferation rate of disseminated tumor cells, and ultimately lead to a significant reduction in metastasis and recurrence, thereby enhancing the efficacy of chemotherapy. Based on preclinical studies, the investigators designed this study to enroll mTNBC patients who have progressed during or following chemotherapy, and to explore the efficacy of combined treatment of dasatinib, quercetin with chemotherapy at a clinical level, providing new strategies of combined treatment for TNBC patients.

Enrollment

10 estimated patients

Sex

Female

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

ECOG Performance Status of 0, 1
Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression)
Radiologic/objective evidence of recurrence or disease progression after chemotherapy for metastatic breast cancer (MBC)
Adequate hematologic and end-organ function, laboratory test results, obtained within 14 days prior to initiation of study treatment.
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures as outlined for each specific treatment arm
Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1)
have the cognitive ability to understand the protocol and be willing to participate and to be followed up

Exclusion criteria

Symptomatic, untreated, or actively progressing CNS metastases
Active or history of autoimmune disease or immune deficiency
Significant cardiovascular disease
History of malignancy other than breast cancer within 5 years prior to screening, with the exception of those with a negligible risk of metastasis or death
Treatment with chemotherapy, radiotherapy,immunotherapy or surgery (outpatient clinic surgery excluded) within 3 weeks prior to initiation of study treatment.
Pregnancy or breastfeeding, or intention of becoming pregnant during the study
History of allergies to the drug components of this trial
Patients who have been using oral steroid hormones for a long time will need to stop for 4 weeks if they have used them occasionally in the past